Eris Lifesciences Limited (ERIS) — Cash Flow-to-Debt Ratio
Eris Lifesciences Limited (ERIS) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of Rs2.39 Billion could theoretically repay 0% of its total liabilities (Rs36.56 Billion) in one year. Explore Eris Lifesciences Limited strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eris Lifesciences Limited Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Eris Lifesciences Limited across 14 annual periods. Also explore ERIS total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Eris Lifesciences Limited (2012–2025)
Year-by-year debt coverage analysis for Eris Lifesciences Limited. For market capitalisation and broader financial context, see Eris Lifesciences Limited stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.28x | Rs10.65 Billion | Rs37.61 Billion | ▲ +122.9% |
| 2024 | 0.13x | Rs4.86 Billion | Rs38.27 Billion | ▼ -37.0% |
| 2023 | 0.20x | Rs2.92 Billion | Rs14.47 Billion | ▼ -80.6% |
| 2022 | 1.04x | Rs3.78 Billion | Rs3.64 Billion | ▼ -28.5% |
| 2021 | 1.45x | Rs3.75 Billion | Rs2.58 Billion | ▲ +37.2% |
| 2020 | 1.06x | Rs2.71 Billion | Rs2.56 Billion | ▲ +82.8% |
| 2019 | 0.58x | Rs2.23 Billion | Rs3.85 Billion | ▲ +41.8% |
| 2018 | 0.41x | Rs2.35 Billion | Rs5.74 Billion | ▼ -79.3% |
| 2017 | 1.98x | Rs2.00 Billion | Rs1.01 Billion | ▲ +42.2% |
| 2016 | 1.39x | Rs1.31 Billion | Rs945.34 Million | ▲ +35.4% |
| 2015 | 1.03x | Rs900.57 Million | Rs876.95 Million | ▲ +2.8% |
| 2014 | 1.00x | Rs896.24 Million | Rs897.40 Million | ▲ +60.2% |
| 2013 | 0.62x | Rs380.15 Million | Rs609.72 Million | ▲ +1.1% |
| 2012 | 0.62x | Rs302.99 Million | Rs491.55 Million | — |